MA32940B1 - Composes organiques - Google Patents

Composes organiques

Info

Publication number
MA32940B1
MA32940B1 MA33971A MA33971A MA32940B1 MA 32940 B1 MA32940 B1 MA 32940B1 MA 33971 A MA33971 A MA 33971A MA 33971 A MA33971 A MA 33971A MA 32940 B1 MA32940 B1 MA 32940B1
Authority
MA
Morocco
Prior art keywords
pyrazolo
pyrimidin
imino
dihydro
ones
Prior art date
Application number
MA33971A
Other languages
Arabic (ar)
English (en)
Inventor
Jun Zhao
Hailin Zeng
Peng Li
Lawrence P Wennogle
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42233537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32940(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MA32940B1 publication Critical patent/MA32940B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES 3-AMINO-4,5-DIHYDRO-(1H OU 2H)-PYRAZOLO[3,4-D]PYRIMIDIN-6(7H)-ONES AINSI QUE LEURS DÉRIVÉS 4-IMINO OU 4-THIOXO, PAR EXEMPLE LES 3-AMINO-4-(THIOXO OU IMINO)-4,5-DIHYDRO-2H-PYRAZOLO[3,4-D]PYRIMIDIN-6(7H)-ONES, LES 3-AMINO-4-(THIOXO OU IMINO)-4,5-DIHYDRO-2H-PYRAZOLO[3,4-D]PYRIMIDIN-6(7H)-ONES, LES 3-AMINO-4-(THIOXO OU IMINO)-4,5-DIHYDRO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6(7H)-ONES, LEURS PROCÉDÉS DE PRODUCTION, LEUR EMPLOI EN TANT QUE PRODUITS PHARMACEUTIQUES ET LES COMPOSITIONS PHARMACEUTIQUES LES INCLUANT.
MA33971A 2008-12-06 2009-12-07 Composes organiques MA32940B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12043808P 2008-12-06 2008-12-06
PCT/US2009/006444 WO2010065153A1 (fr) 2008-12-06 2009-12-07 Composés organiques

Publications (1)

Publication Number Publication Date
MA32940B1 true MA32940B1 (fr) 2012-01-02

Family

ID=42233537

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33971A MA32940B1 (fr) 2008-12-06 2009-12-07 Composes organiques

Country Status (22)

Country Link
US (2) US8697710B2 (fr)
EP (1) EP2367431B1 (fr)
JP (1) JP5710493B2 (fr)
KR (1) KR20110098732A (fr)
CN (1) CN102223799A (fr)
AU (1) AU2009322905A1 (fr)
BR (1) BRPI0922700A2 (fr)
CA (1) CA2740398A1 (fr)
CO (1) CO6390079A2 (fr)
CR (1) CR20110310A (fr)
DO (1) DOP2011000174A (fr)
EA (1) EA201170773A1 (fr)
EC (1) ECSP11011180A (fr)
ES (1) ES2551325T3 (fr)
GE (1) GEP20146029B (fr)
IL (1) IL213311A0 (fr)
MA (1) MA32940B1 (fr)
MX (1) MX2011005932A (fr)
PE (1) PE20110944A1 (fr)
TN (1) TN2011000249A1 (fr)
WO (1) WO2010065153A1 (fr)
ZA (1) ZA201103634B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5084725B2 (ja) 2005-06-06 2012-11-28 武田薬品工業株式会社 有機化合物
WO2007143705A2 (fr) 2006-06-06 2007-12-13 Intra-Cellular Therapies, Inc. Composés organiques
EP2081431B1 (fr) * 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Composés organiques
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
JP5701608B2 (ja) * 2007-12-06 2015-04-15 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
CN104370918A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
BRPI0922131A2 (pt) * 2008-12-06 2015-08-18 Intracellular Therapies Inc Compostos orgânicos
EP2367430B1 (fr) 2008-12-06 2014-08-13 Intra-Cellular Therapies, Inc. Composés organiques
BRPI0922808A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
BRPI0922809A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
MX2011005933A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
US11464781B2 (en) 2009-02-25 2022-10-11 Intra-Cellular Therapies, Inc. PDE1 inhibitors for ophthalmic disorders
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP2013507360A (ja) 2009-10-08 2013-03-04 イントラ−セルラー・セラピーズ・インコーポレイテッド ホスホジエステラーゼ１−標的トレーサーおよび方法
EP2590657A4 (fr) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc Composés organiques
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153138A1 (fr) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Composés organiques
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
WO2012171016A1 (fr) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Composés organiques
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AU2013277294C1 (en) 2012-06-18 2018-02-08 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
EP2956141A4 (fr) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc Nouvelles utilisations
EP2968338B1 (fr) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Inhibiteurs de pde1 utilisés dans le traitement et/ou la prévention de blessures du snc et de maladies, de troubles ou de blessures du snp
PL2970279T3 (pl) 2013-03-15 2021-05-31 Intra-Cellular Therapies, Inc. Związki organiczne
US9849132B2 (en) 2014-01-08 2017-12-26 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
DK3157926T3 (da) 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
RU2711442C2 (ru) * 2014-09-17 2020-01-17 Интра-Селлулар Терапиз, Инк. Соединения и способы
US10105349B2 (en) 2014-12-06 2018-10-23 Intra-Cellular Therapies, Inc. Organic compounds
MX371158B (es) 2014-12-06 2020-01-20 Intra Cellular Therapies Inc Compuestos inhibidores de pde2.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
EP3509589B1 (fr) 2016-09-12 2021-11-17 Intra-Cellular Therapies, Inc. Nouvelles utilisations
JOP20190126A1 (ar) * 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
JP7254078B2 (ja) 2017-11-27 2023-04-07 ダート・ニューロサイエンス・エルエルシー Ｐｄｅ１阻害剤としての置換フラノピリミジン化合物
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
RS62551B1 (sr) 2017-12-14 2021-12-31 H Lundbeck As Kombinovane terapije koje obuhvataju primenu 1h-pirazolo[4,3-b]piridina
TW201927784A (zh) 2017-12-20 2019-07-16 丹麥商Ｈ 朗德貝克公司 作為pde1抑制劑之大環
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
EP3728250A1 (fr) 2017-12-20 2020-10-28 H. Lundbeck A/S PYRAZOLO[3,4-beta]PYRIDINES ET IMIDAZO[1,5-beta]PYRIDAZINES UTILISÉES EN TANT QU'INHIBITEURS DE PDE1
US11839614B2 (en) 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
EP3802545A4 (fr) 2018-05-25 2022-03-16 Intra-Cellular Therapies, Inc. Composés organiques
US20210338679A1 (en) 2018-09-25 2021-11-04 Intra-Cellular Therapies, Inc. Novel uses
US11628171B2 (en) 2019-03-13 2023-04-18 Children's Medical Center Corporation Method for treating brain or nerve injury
WO2020210614A1 (fr) 2019-04-12 2020-10-15 Intra-Cellular Therapies, Inc. Composés organiques
JP7612672B2 (ja) 2019-09-03 2025-01-14 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規化合物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689863A (en) 1969-12-08 1972-09-05 Matsushita Electric Industrial Co Ltd Voltage dependent resistors in a surface barrier type
GB1447426A (en) 1974-03-20 1976-08-25 Lepetit Spa Pyrrolo 3,4-d- pyrimidines and methods for their preparation
JPS6032638B2 (ja) 1976-09-01 1985-07-29 武田薬品工業株式会社 ３−アミノピラゾロ〔３，４−ｄ〕ピリミジン誘導体
JPS58500966A (ja) 1981-04-22 1983-06-09 ビイク　グルデン　ロンベルク　ヒエ−ミツシエ　フアブリ−ク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 新規ピラゾロ〔３，４−ｄ〕ピリミジン、その製法及びこれを含有する医薬品
US4603203A (en) 1983-12-14 1986-07-29 Takeda Chemical Industries, Ltd. 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof
US4663326A (en) 1985-04-04 1987-05-05 Warner-Lambert Company Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
EP0237289A3 (fr) 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Dérivés de pyrazolo[3,4-d]pyrimidine, leur préparation et utilisation
JPS6310788A (ja) 1986-03-14 1988-01-18 Takeda Chem Ind Ltd ３−アミノピラゾロ〔３，４−ｄ〕ピリミジン誘導体
US4912104A (en) 1987-08-31 1990-03-27 Takeda Chemical Industries, Ltd. Tricyclic fused pryimidine derivatives, and their use as pharmaceuticals
JPH01265027A (ja) 1988-04-14 1989-10-23 Takeda Chem Ind Ltd 肝疾患治療剤
EP0353941A3 (fr) 1988-08-02 1991-05-02 Takeda Chemical Industries, Ltd. Médicament contre le psoriasis renfermant des dérivées de la 3-aminopyrazolo [3,4-d]pyrimidine
JP3116230B2 (ja) 1989-02-15 2000-12-11 武田薬品工業株式会社 三環式縮合ピリミジン誘導体
JPH02289518A (ja) 1989-02-15 1990-11-29 Takeda Chem Ind Ltd アデノシン拮抗剤
KR920004437B1 (ko) 1989-09-12 1992-06-05 삼성전자 주식회사 금전등록기의 거래선 관리방법
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
IL98559A0 (en) 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
DE69132291T2 (de) 1990-12-21 2000-12-14 Beecham Group P.L.C., Brentford Xanthinderivate
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5223501A (en) 1991-05-10 1993-06-29 Merck & Co., Inc. Substituted pyrimidinones bearing acidic functional groups as angiotensin ii antagonists
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
NZ262797A (en) 1993-02-26 1997-08-22 Schering Corp Polycyclic guanine derivatives, purine and pyrimidine precursors; medicaments
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
GB9626643D0 (en) 1996-12-21 1997-02-12 Astra Pharma Prod Compounds
DE19709126A1 (de) 1997-03-06 1998-09-10 Bayer Ag Arylamin-, -oxy-, -thio-substituierte Dihydropurinone und Pyrazolopyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
ES2356886T3 (es) 1998-03-31 2011-04-14 Kyowa Hakko Kirin Co., Ltd. Compuestos heterocíclicos nitrogenados.
US6133273A (en) 1998-05-08 2000-10-17 American Home Products Corporation Pyrazolopyrimidine-2,4-dione sulfonamides
US6166019A (en) 1998-07-16 2000-12-26 Abbott Laboratories Piperazinyl pyrimidine dione compounds selective for adrenoceptors
DE60006541D1 (de) 1999-06-30 2003-12-18 Merck & Co Inc Src-kinase hemmende verbindungen
DE19931206A1 (de) 1999-07-07 2001-01-11 Stief Christian Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
KR20020038941A (ko) 1999-10-11 2002-05-24 디. 제이. 우드, 스피겔 알렌 제이 포스포디에스테라아제 억제제로서의5-(2-치환된-5-헤테로사이클릴설포닐피리드-3-일)-디하이드로피라졸로[4,3-ｄ]피리미딘-7-온
IL139073A0 (en) 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
IL139454A0 (en) 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
AU2001255849B8 (en) 2000-04-19 2006-04-27 Lilly Icos, Llc. PDE-V inhibitors for treatment of Parkinson's Disease
WO2002074312A1 (fr) 2001-03-16 2002-09-26 Pfizer Limited Composes pyrazolo[4,3-d]pyrimidinone en tant qu'inhibiteurs de gmpc pde
WO2002088079A2 (fr) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Inhibiteurs doubles de pde 7 et pde 4
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
ATE395349T1 (de) 2001-08-28 2008-05-15 Schering Corp Polycyclische guanin phosphodiesterase inhibitoren
US20030211040A1 (en) 2001-08-31 2003-11-13 Paul Greengard Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
SE0203825D0 (sv) * 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US20050048573A1 (en) 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
WO2004087906A1 (fr) 2003-03-31 2004-10-14 Pfizer Products Inc. Structure cristalline de 3',5'-phosphodiesterase nucleotidique cyclique 1d(pde1b) et ses utilisations
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
EP1636229A4 (fr) 2003-06-06 2008-07-30 Endacea Inc Antagonistes du recepteur d'adenosine a1
US7557113B2 (en) 2003-08-26 2009-07-07 Teijin Pharma Limited Substituted pyrrolo[3,2-d]pyrimidine derivatives
AP2006003559A0 (en) 2003-09-05 2006-04-30 Neurogen Corp Ventis Pharmaceuticals Inc Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF 1 receptor ligands
JP5084725B2 (ja) 2005-06-06 2012-11-28 武田薬品工業株式会社 有機化合物
US20080194592A1 (en) 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
EP1931668A2 (fr) 2005-09-16 2008-06-18 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridines substituées en tant qu'inhibiteurs de la phosphodiesterase
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
WO2007143705A2 (fr) * 2006-06-06 2007-12-13 Intra-Cellular Therapies, Inc. Composés organiques
US20070286890A1 (en) 2006-06-07 2007-12-13 John Garnett Walt Eyelash applicator and method
US20090137549A1 (en) 2006-11-09 2009-05-28 Paul John Edward Novel compounds useful for the treatment of degenerative & inflamatory diseases
EP2081431B1 (fr) 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Composés organiques
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
JP5701608B2 (ja) 2007-12-06 2015-04-15 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
CN104370918A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
AU2009239536C1 (en) 2008-04-22 2012-12-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
BRPI0922808A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
EP2367430B1 (fr) 2008-12-06 2014-08-13 Intra-Cellular Therapies, Inc. Composés organiques
BRPI0922809A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
BRPI0922131A2 (pt) 2008-12-06 2015-08-18 Intracellular Therapies Inc Compostos orgânicos
MX2011005933A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP2013507360A (ja) 2009-10-08 2013-03-04 イントラ−セルラー・セラピーズ・インコーポレイテッド ホスホジエステラーゼ１−標的トレーサーおよび方法
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153138A1 (fr) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Composés organiques
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
EP2590657A4 (fr) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc Composés organiques
WO2012171016A1 (fr) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Composés organiques

Also Published As

Publication number Publication date
JP5710493B2 (ja) 2015-04-30
DOP2011000174A (es) 2011-10-31
ECSP11011180A (es) 2011-10-31
EP2367431A4 (fr) 2012-08-15
JP2012510996A (ja) 2012-05-17
US8697710B2 (en) 2014-04-15
MX2011005932A (es) 2011-12-16
EP2367431B1 (fr) 2015-08-05
US20120094966A1 (en) 2012-04-19
ZA201103634B (en) 2013-05-29
IL213311A0 (en) 2011-07-31
WO2010065153A1 (fr) 2010-06-10
US20140315868A1 (en) 2014-10-23
KR20110098732A (ko) 2011-09-01
GEP20146029B (en) 2014-02-10
EA201170773A1 (ru) 2012-01-30
AU2009322905A1 (en) 2010-06-10
CN102223799A (zh) 2011-10-19
CA2740398A1 (fr) 2010-06-10
ES2551325T3 (es) 2015-11-18
EP2367431A1 (fr) 2011-09-28
CO6390079A2 (es) 2012-02-29
CR20110310A (es) 2011-10-28
TN2011000249A1 (en) 2012-12-17
PE20110944A1 (es) 2012-01-25
BRPI0922700A2 (pt) 2015-08-11

Similar Documents

Publication Publication Date Title
MA32940B1 (fr) Composes organiques
MA32942B1 (fr) Composes organiques
WO2009111653A3 (fr) Agents thérapeutiques antiviraux
WO2009005677A3 (fr) Composés antiviraux
WO2009005676A3 (fr) Composés antiviraux
WO2008005565A3 (fr) Composés antiviraux de phosphinate
MA32941B1 (fr) Composes organiques
WO2006110157A3 (fr) Analogues phosphonates de composes inhibiteurs du vih
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
WO2006020276A3 (fr) Composés antiviraux
GEP20135780B (en) Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer agents
TN2011000244A1 (en) Organic compounds
NO20076371L (no) Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
JO2910B1 (en) Organic compounds
MA30226B1 (fr) Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique.
WO2010049454A3 (fr) Composition antimicrobienne tirée de copépodes
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
WO2007100610A3 (fr) Derives de pyridine, de pyrimidine et de pyrazine en tant que modulateurs du recepteur cxcr3
WO2007097981A3 (fr) Alpha carbolines et leurs utilisations
FR3041639B1 (fr) NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
CR9182A (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
WO2007070433A3 (fr) Derives de 2-arylthiazole en tant que modulateurs du recepteur cxcr3
WO2007014352A3 (fr) Composes antiviraux
WO2009040314A3 (fr) Nouveaux dérivés de l'acétone substitués par un hétéroaryle, appropriés comme inhibiteurs de la phospholipase a2